As of 2026-09-10, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -3.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 301.75 mil USD. CCCC's TTM EBITDA according to its financial statements is -99.45 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.5x - 18.1x | 17.5x |
| Forward P/E multiples | 20.4x - 23.9x | 21.2x |
| Fair Price | (17.64) - (15.60) | (16.69) |
| Upside | -612.7% - -553.6% | -585.3% |
| Date | EV/EBITDA |
| 2026-09-04 | -3.39 |
| 2026-09-03 | -3.37 |
| 2026-09-02 | -3.42 |
| 2026-09-01 | -3.51 |
| 2026-08-31 | -3.33 |
| 2026-08-28 | -3.49 |
| 2026-08-27 | -3.77 |
| 2026-08-26 | -3.92 |
| 2026-08-25 | -3.88 |
| 2026-08-24 | -3.77 |
| 2026-08-21 | -3.66 |
| 2026-08-20 | -3.69 |
| 2026-08-19 | -3.89 |
| 2026-08-18 | -3.86 |
| 2026-08-17 | -3.95 |
| 2026-08-14 | -3.92 |
| 2026-08-13 | -3.75 |
| 2026-08-12 | -3.55 |
| 2026-08-11 | -3.51 |
| 2026-08-10 | -3.23 |
| 2026-08-07 | -3.36 |
| 2026-08-06 | -3.26 |
| 2026-08-05 | -3.23 |
| 2026-08-04 | -3.22 |
| 2026-08-03 | -3.10 |
| 2026-07-31 | -3.08 |
| 2026-07-30 | -3.28 |
| 2026-07-29 | -3.12 |
| 2026-07-28 | -3.16 |
| 2026-07-27 | -3.20 |
| 2026-07-24 | -2.99 |
| 2026-07-23 | -3.27 |
| 2026-07-22 | -3.37 |
| 2026-07-21 | -3.47 |
| 2026-07-20 | -3.19 |
| 2026-07-17 | -3.31 |
| 2026-07-16 | -3.19 |
| 2026-07-15 | -3.43 |
| 2026-07-14 | -3.45 |
| 2026-07-13 | -3.57 |
| 2026-07-10 | -3.72 |
| 2026-07-09 | -3.98 |
| 2026-07-08 | -3.87 |
| 2026-07-07 | -4.05 |
| 2026-07-06 | -3.81 |
| 2026-07-02 | -3.99 |
| 2026-07-01 | -4.03 |
| 2026-06-30 | -4.40 |
| 2026-06-29 | -4.05 |
| 2026-06-26 | -3.95 |